Skip to main content
SpringerLink
Log in

Effect of a new potent H2-receptor antagonist on meal-stimulated gastric acid secretion and serum gastrin concentration in duodenal ulcer patients

  • Original Articles
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

We evaluated the effect of 20-, 40-, 60-, and 80-mg doses of SKF 93479, a new H2-receptor antagonist, on food-stimulated gastric acid secretion in duodenal ulcer patients. Medications were given as a single oral dose in the morning with a breakfast meal, and acid secretion was measured by in vivo intragastric titration in response to four blended steak meals infused into the stomach at intervals over a 24-hr period. A breakfast meal was infused immediately after medication; a luncheon meal was given 5 hr after drug, and a dinner meal was instilled 10 hr later. A second breakfast meal was infused 24 hr after medication. For comparison, the effect of 300 mg cimetidine, given as normally prescribed (with meals and at bedtime), on acid secretion was also studied. Food-stimulated acid secretion was inhibited in a dose-related manner by each of the four doses of SKF 93479. The antisecretory effect was most dramatic following the luncheon meal, and there was still significant (P<0.05) inhibition of acid secretion at the dinner meal with all doses of SKF 93479. With the second breakfast meal 24 hr after medication, the 80-mg dose alone achieved significant (P<0.05) inhibition of acid secretion. Inhibition of acid secretion was correlated positively with blood SKF 93479 levels. When compared with placebo results, serum gastrin concentration, measured 5 and 10 hr after medication, was significantly higher (P<0.05) with SKF 93479.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Binder HJ, Cocco A, Crossley RJ, Finkelstein W, Font R, Friedman G, Groarke J, Hughes W, Johnson AF, McGuigan JE, Summers R, Vlahcevic R, Wilson EC, Winship DH: Cimetidine in the treatment of duodenal ulcer. A multicenter double blind study. Gastroenterology 74:308–388, 1978

    Google Scholar 

  2. Behar J, Brand DL, Brown FC, Castell DO, Cohen S, Crossley RJ, Pope CE II, Winans CS: Cimetidine in the treatment of symptomatic gastroesophageal reflux. A double blind controlled trial. Gastroenterology 74:441–448, 1978

    Google Scholar 

  3. Isenberg J, Elashoff J, Sandersfeld M, Peterson W: Double blind comparison of cimetidine and low-dose antacid versus placebo in the healing of benign gastric ulcer. Gastroenterology 82:1090, 1982 (abstract)

    Google Scholar 

  4. McCarthy DM: Report on the United States experience with cimetidine in Zollinger-Ellison syndrome and other hypersecretory states. Gastroenterology 74:453–458, 1978

    Google Scholar 

  5. Bradshaw J, Brittain RT, Clitherow JW, Daly MJ, Jack D, Price BJ, Stables R: Ranitidine (AH 19065): A new potent, selective histamine H2-receptor antagonist. Br J Pharmacol 66:464(P), 1979

    Google Scholar 

  6. Brater DC, Peters MN, Eshelman FN, Richardson CT: Clinical comparison of cimetidine and ranitidine. Clin Pharmacol Ther 32:484–489, 1982

    Google Scholar 

  7. Blakemore RC, Brown TH, Durant GJ, Ganellin CR, Parson ME, Rasmussen AC, Rawlins DA: SKF 93479, A potent and long-acting histamine H2-receptor antagonist. Br J Pharmacol 74:200, 1981

    Google Scholar 

  8. Fordtran JS, Walsh JH: Gastric acid secretion rate and buffer content of the stomach after eating. Results in normal subjects and in patients with duodenal ulcer. J Clin Invest 52:645–657, 1973

    Google Scholar 

  9. Henn RM, Isenberg JI, Maxwell V, Sturdevant RAL: Inhibition of gastric acid secretion by cimetidine in patients with duodenal ulcer. N Engl J Med 293(8):371–375, 1975

    Google Scholar 

  10. Walsh JH: Radioimmunoassay of gastrin.In Nuclear MedicineIn Vitro, Vol 1. B Rothfield (ed). Philadelphia, JG Lippincott Company, 1974, pp 248–271

    Google Scholar 

  11. Armitage P: Statistical Methods in Medical Research. New York, John Wiley & Sons, 1979, pp 99–118

    Google Scholar 

  12. Walkenstein SS, Dubb JW, Randolph WC, Westlake WJ, Stote RM, Intoccia AP: Bioavailability of cimetidine in man. Gastroenterology 74:360–365, 1978

    Google Scholar 

  13. Blackwell B: Drug therapy-patient compliance. N Engl J Med 289:249–252, 1973

    Google Scholar 

  14. Gatley MS: To be taken as directed. J R Coll Gen Pract 16:39–44, 1968

    Google Scholar 

  15. Brogden RM, Heel RC, Speight TM, Avery GS: Cimetidine: A review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease. Drugs 15:93–131, 1978

    Google Scholar 

  16. Hansky J, Stern AI, Korman MG, Waugh J: Effects of longterm cimetidine on serum gastrin in duodenal ulcer. Dig Dis Sci 24:468–470, 1979

    Google Scholar 

  17. Johnson LR: Regulation of gastrointestinal growth.In Physiology of the Gastrointestinal Tract, Vol 1. LR Johnson (ed.) New York, Raven Press, 1981, pp 169–196

    Google Scholar 

  18. Witzel L, Halter F, Olah AF, Hacki WH: Effects of prolonged metiamide medication on the fundic mucosa. Gastroenterology 73:797–803, 1977

    Google Scholar 

  19. Blackwood WS, Maudgal DP, Northfield TC: Prevention by bedtime cimetidine of duodenal ulcer relapse. Lancet 1:626–627, 1978

    Google Scholar 

  20. Burland WL, Hawkins BW, Horton RJ, Beresford J: The longer-term treatment of duodenal ulcer with cimetidine.In Cimetidine: The Westminster Hospital Symposium. C Wastell, P Lance (eds.). Edinburgh, Churchill Livingston, 1978, pp 66–78

    Google Scholar 

  21. Boyd EJS, Peden NR, Browning MCK, Saunders JHB, Wormsley KG: Clinical and endocrine aspects of treatment with ranitidine. Scand J Gastroenterol 16(Suppl 69):81–83, 1981

    Google Scholar 

  22. Milton-Thompson GJ, Ahmet Z, Lightfoot NF, Hunt RH, Barnard J, Brimblecombe RW, Moore PJ, Bavin PMG, Darkin DW, Viney N: Intragastric acidity, bacteria, nitrite, andN-nitroso compounds before, during and after cimetidine treatment. Lancet 1:1091–1095, 1982

    Google Scholar 

  23. Muscroft TJ, Youngs DJ, Burdon DW, Keighley MRB: Cimetidine is unlikely to increase formation of intragastricN-nitroso compounds in patients taking a normal diet. Lancet 1:408–410, 1981

    Google Scholar 

  24. Reed PI, Smith PLR, Haines K, House FR, Walters CL: Gastric juiceN-nitrosamines in health and gastroduodenal disease. Lancet 2:550–552, 1981

    Google Scholar 

  25. Freston JW: Cimetidine. II adverse reactions and patterns of use. Ann Intern Med 97:728–734, 1982

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Gastroenterology Division, University of California San Diego Medical Center, Dallas, Texas

    Steven Brozinsky, Daniel L. Hogan, Jon I. Isenberg & Charles T. Richardson

  2. Department of Internal Medicine, Gastroenterology Division, Veterans Administration Medical Centers San Diego and Dallas, Dallas, Texas

    Steven Brozinsky, Daniel L. Hogan, Jon I. Isenberg & Charles T. Richardson

  3. Department of Internal Medicine, Gastroenterology Division, the University of Texas Southwestern Medical School, Dallas, Texas

    Steven Brozinsky, Daniel L. Hogan, Jon I. Isenberg & Charles T. Richardson

Authors
  1. Steven Brozinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel L. Hogan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jon I. Isenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Charles T. Richardson
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported by grant AM 17328 to the Center for Ulcer Research and Education (CURE)_and grant 16816 from the National Institute of Health. Smith, Kline and French Laboratories supplied medications and provided additional financial support for these studies.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brozinsky, S., Hogan, D.L., Isenberg, J.I. et al. Effect of a new potent H2-receptor antagonist on meal-stimulated gastric acid secretion and serum gastrin concentration in duodenal ulcer patients. Digest Dis Sci 29, 129–133 (1984). https://doi.org/10.1007/BF01317053

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01317053

Keywords

Search

Navigation